By combining radiotherapy with agents that modulate the expression or activity of TP53, ATM, RAD51, and BAX, we may overcome the resistance mechanisms that limit the effectiveness of radiation therapy in gastric cancer patients. The gene discussed is TP53; the disease is gastric cancer.